| US 7,531,530 B2 | ||
| Therapeutic compounds | ||
| Thomas Helleday, Stockholm (Sweden); and Nicola Curtin, Tyne and Wear (United Kingdom) | ||
| Assigned to Cancer Research Technology Limited, London (United Kingdom); and Pfizer, New York, N.Y. (US) | ||
| Appl. No. 10/565,308 PCT Filed Jul. 23, 2004, PCT No. PCT/GB2004/003183 § 371(c)(1), (2), (4) Date Mar. 27, 2006, PCT Pub. No. WO2005/012305, PCT Pub. Date Feb. 10, 2005. |
||
| Claims priority of application No. 0317466.1 (GB), filed on Jul. 25, 2003; and application No. 0408524.7 (GB), filed on Apr. 16, 2004. | ||
| Prior Publication US 2007/0072841 A1, Mar. 29, 2007 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. A61P 35/00 (2006.01) | ||
| U.S. Cl. 514—212.06 [514/220] | 15 Claims |
| 1. A method for treating cancer in a mammal, wherein the cancer is of a type that is caused by a genetic defect in a gene
that mediates homologous recombination and is selected from the group consisting of cancer of the: breast, lung, colon, pancreas,
stomach, ovary, cervix, breast, prostate, bone, brain, and skin, the gene that mediates homologous recombination being selected
from the group consisting of: XRCC1, CTPS, RPA, RPA1, RPA2, RPA3, XPD, ERCC1, XPF, MMS19, RAD51, RAD51, RAD51C, RAD51D, DMC1,
XRCCR, XRCC3, BRCA1, BRCA2, RAD52, RAD54, RAD50, MRE11, NB51, WRN, BLM KU70, KU80, ATM, ATR CHK1, CHK2, FANCA, FANCB, FANCC,
FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, RAD1, RAD9 and combinations thereof, the
method comprising:
selecting the mammal having said genetic defect; and
administering to the mammal a compound selected from the group consisting of a compound of the formula I, formula II and formula
III:
 |